Pyxis Oncology reported a wider-than-expected net loss of $0.40 per share for the second quarter 2026, missing analyst estimates of a $0.34 loss. The company generated zero milestone revenue during the quarter, slightly below the nominal expectations for the period. Management emphasized that its recent private placement financing has significantly bolstered the balance sheet, providing a cash runway that now extends into the second quarter of 2027 to support upcoming clinical readouts.
Key Highlights
- Net loss increased to $25.3 million compared to $18.4 million in the prior-year period, primarily due to an 83% surge in G&A expenses to $9.9 million.
- The company ended the quarter with $34.5 million in cash and short-term investments, supplemented by an additional $50 million in upfront gross proceeds from a private placement completed in July.
- Clinical timelines for lead candidate MICVO remain on track, with updated monotherapy data expected in Fall 2026 and combination data with pembrolizumab scheduled for the fourth quarter of 2026.